Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng JiangDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USAShengqing GuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USADeng PanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USAJingxin FuSchool of Life Science and Technology, Tongji University, Shanghai, ChinaAvinash SahuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USAXihao HuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USAZiyi LiSchool of Life Science and Technology, Tongji University, Shanghai, ChinaNicole TraughDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAXia BuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USABo LiDepartment of Bioinformatics, UT Southwestern, Dallas, TX, USAJun LiuDepartment of Statistics, Harvard University, Cambridge, MA, USAGordon J. FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAMyles BrownCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USAKai W. WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected]X. Shirley LiuCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected]
2018en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0